RT Journal Article
SR Electronic
T1 Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.26.21252554
DO 10.1101/2021.02.26.21252554
A1 Nuno R. Faria
A1 Thomas A. Mellan
A1 Charles Whittaker
A1 Ingra M. Claro
A1 Darlan da S. Candido
A1 Swapnil Mishra
A1 Myuki A. E. Crispim
A1 Flavia C. Sales
A1 Iwona Hawryluk
A1 John T. McCrone
A1 Ruben J. G. Hulswit
A1 Lucas A. M. Franco
A1 Mariana S. Ramundo
A1 Jaqueline G. de Jesus
A1 Pamela S. Andrade
A1 Thais M. Coletti
A1 Giulia M. Ferreira
A1 Camila A. M. Silva
A1 Erika R. Manuli
A1 Rafael H. M. Pereira
A1 Pedro S. Peixoto
A1 Moritz U. Kraemer
A1 Nelson Gaburo, Jr.
A1 Cecilia da C. Camilo
A1 Henrique Hoeltgebaum
A1 William M. Souza
A1 Esmenia C. Rocha
A1 Leandro M. de Souza
A1 Mariana C. de Pinho
A1 Leonardo J. T Araujo
A1 Frederico S. V. Malta
A1 Aline B. de Lima
A1 Joice do P. Silva
A1 Danielle A. G. Zauli
A1 Alessandro C. de S. Ferreira
A1 Ricardo P Schnekenberg
A1 Daniel J. Laydon
A1 Patrick G. T. Walker
A1 Hannah M. Schlüter
A1 Ana L. P. dos Santos
A1 Maria S. Vidal
A1 Valentina S. Del Caro
A1 Rosinaldo M. F. Filho
A1 Helem M. dos Santos
A1 Renato S. Aguiar
A1 José L. P. Modena
A1 Bruce Nelson
A1 James A. Hay
A1 Melodie Monod
A1 Xenia Miscouridou
A1 Helen Coupland
A1 Raphael Sonabend
A1 Michaela Vollmer
A1 Axel Gandy
A1 Marc A. Suchard
A1 Thomas A. Bowden
A1 Sergei L. K. Pond
A1 Chieh-Hsi Wu
A1 Oliver Ratmann
A1 Neil M. Ferguson
A1 Christopher Dye
A1 Nick J. Loman
A1 Philippe Lemey
A1 Andrew Rambaut
A1 Nelson A. Fraiji
A1 Maria do P. S. S. Carvalho
A1 Oliver G. Pybus
A1 Seth Flaxman
A1 Samir Bhatt
A1 Ester C. Sabino
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.02.26.21252554.abstract
AB Cases of SARS-CoV-2 infection in Manaus, Brazil, resurged in late 2020, despite high levels of previous infection there. Through genome sequencing of viruses sampled in Manaus between November 2020 and January 2021, we identified the emergence and circulation of a novel SARS-CoV-2 variant of concern, lineage P.1, that acquired 17 mutations, including a trio in the spike protein (K417T, E484K and N501Y) associated with increased binding to the human ACE2 receptor. Molecular clock analysis shows that P.1 emergence occurred around early November 2020 and was preceded by a period of faster molecular evolution. Using a two-category dynamical model that integrates genomic and mortality data, we estimate that P.1 may be 1.4–2.2 times more transmissible and 25-61% more likely to evade protective immunity elicited by previous infection with non-P.1 lineages. Enhanced global genomic surveillance of variants of concern, which may exhibit increased transmissibility and/or immune evasion, is critical to accelerate pandemic responsiveness.One-Sentence Summary We report the evolution and emergence of a SARS-CoV-2 lineage of concern associated with rapid transmission in Manaus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by a Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0) (caddecentre.org/). FAPESP further supports IMC (2018/17176-8 and 2019/12000-1), F.C.S.S. (2018/25468-9), JGJ (2018/17176-8 and 2019/12000-1, 18/14389-0), TMC (2019/07544-2), CAMS (2019/21301-5), WMS (2017/13981-0, 2019/24251-9), LMS (FAPESP 2020/04272-9), MCP (FAPESP 2019/21568-1) and P.S.P. (16/18445-7). N.R.F. is supported by a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (204311/Z/16/Z). DSC is supported by the Clarendon Fund and by the Department of Zoology, University of Oxford. This project was supported by CNPq (RSA: 312688/2017-2 and 439119/2018-9; and WMS: 408338/2018-0), FAPERJ (RSA: 202.922/2018). MSR is supported by FFMUSP (FFMUSP 206.706). HS is supported by Imperial College Covid-19 Research Fund. GMF is supported by CAPES. PL, AR, and NJL are supported by the Wellcome Trust ARTIC network (collaborators award no. 206298/Z/17/Z). PL and AR are supported by the European Research Council (grant no. 725422 -ReservoirDOCS). PL is further supported by the European Unions Horizon 2020 project MOOD (874850). MAS is supported by US National Institutes of Health (U19 AI135995). OGP is supported by the Oxford Martin School. SF is supported by the Imperial College Covid-19 Research Fund and EPSRC (EP/V002910/1). SB is supported by BMGF, UKRI, Novo Nordisk Foundation, Academy of Medical Sciences, BRC and MRC. ECS is supported by FAPESP (18/14389-0). We acknowledge support from the Rede Corona-omica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP 01.20.0029.000462/20, CNPq 404096/2020-4). This work received funding from the U.K. Medical Research Council under a concordat with the U.K. Department for International Development. We additionally acknowledge support from Community Jameel and the NIHR Health Protection Research Unit in Modelling Methodology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was confirmed by the national ethical review board (Comissao Nacional de Etica em Pesquisa), protocol number CAAE 30127020.0.0000.0068.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPreliminary genome sequences generated from samples obtained from laboratory A were shared on GISAID on 12 January 2021. Findings were shared with representatives from the World Health Organization, Pan American Health Organization, Secretary of Health Amazonas, and FioCruz Manaus on 11 January 2021. Preliminary report describing first P.1 genomes from Manaus was shared on 12 January 2021 (86). Epidemiological data and epidemiological model code, together with BEAST XML files, tree files, log files are archived at https://github.com/CADDE-CENTRE. GISAID IDs for the SARS-CoV-2 Manaus sequence data can be found in Data S2. All consensus sequences generated by this study can be found at https://github.com/CADDE-CENTRE.